Glenmark Pharma gets tentative nod from USFDA for acne treatment drug
PTI, Jun 20, 2019, 11:56 AM IST
New Delhi: Glenmark Pharmaceuticals Thursday it has received tentative approval from the US health regulator for Clindamycin Phosphate Foam, used to treat acne.
The approved product is a generic version of Mylan Pharmaceuticals’ Evoclin Foam.
Glenmark Pharmaceuticals, USA, has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the company said in a BSE filing.
For the 12 months to April 2019, Evoclin Foam market achieved annual sales of approximately USD 17 million, Glenmark said, citing IQVIA sales data.
The company’s current portfolio consists of 156 products authorised for distribution at the US marketplace and 59 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.
The company’s stock was trading 0.21 per cent lower at Rs 508.50 apiece on BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Markets surrender early gains to trade lower
US Fed interest rate decision key event to watch out for this week: Analysts
DGCA sticks to June 1 deadline for revised flight duty norms; says aim is to alleviate pilot fatigue
Govt approves 17% wage hike for 1.10 lakh employees of LIC
Air India lays off over 180 non-flying staff
MUST WATCH
Latest Additions
Man jumps off third floor of Mantralaya building in Mumbai, lands on safety net
Lok Sabha polls: 4,914 weapon holders in Jammu directed to deposit firearms with police
‘Overseas Friends of BJP’ organises Silicon Valley ‘havan’ to pray for PM Modi’s re-election
I am tough guy to handle but KKR would be at better place by the time I leave: Gambhir
Defence minister Rajnath Singh and Austin discuss growing momentum in defence ties between India and US